Winship receives $7.8 million for multiple myeloma research

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Winship Cancer Institute of Emory University received $7.8 million from the Paula and Rodger Riney Foundation to fund the Riney Family Multiple Myeloma Research Program Fund.

The two-year project will support fast-tracked research projects at Winship in multiple myeloma.

Rodger Riney, founder of the brokerage firm Scottrade Financial Services, was diagnosed with multiple myeloma in 2015. Rodger and his wife Paula Riney have made substantial gifts to the Washington University School of Medicine in St. Louis and to Dana-Farber Cancer Institute in Boston to accelerate research into multiple myeloma and improve outcomes for patients.

Winship has played a role in the development, testing, and approval of multiple myeloma treatments in recent years, including several recently approved immunotherapy drugs.

For the two-year funding period, Lonial and the Winship myeloma team have proposed projects in fundamental research in the underlying biology of multiple myeloma, translational research in the development of new treatments, and clinical research in understanding response rates and drug resistance, among other areas.

The Riney Family Multiple Myeloma Research Program Fund will engage faculty from all four Winship research programs: cancer immunology, cancer prevention and control, cell and molecular biology, and discovery and developmental therapeutics.

Table of Contents

YOU MAY BE INTERESTED IN

George F. Tidmarsh has resigned from his job as director of the FDA Center for Drug Evaluation and Research in the aftermath of a lawsuit by a former associate and a probe into what an HHS spokesperson described as “serious concerns about his personal conduct.”
Research has shown that delivering tumor profiling results to cancer patients prior to initiation of treatment and connecting patients harboring an actionable oncogenic mutation with the right targeted therapy can deliver superior patient outcomes. To fulfill this promise of precision medicine, we need to ensure more targeted therapies are available to patients who need them. Fortunately, this work is well underway. xxx:more

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login